Results from the trial are expected in the first half of 2020 and the information would be used to design and plan any further clinical development Biopharmaceutical firm Otonomy, Inc., has reportedly initiated the Phase 1/2 clinical trial....

The browser would leverage a new blacklist of websites which are recognized as using scripts for cryptomining or fingerprinting Reports suggest that Firefox’s upcoming release would provide users the option to block two increasingly ....

SAFR™ for Security delivers high-performance and has remarkably accurate facial recognition to help security teams in protecting facilities, people and assets more effectively RealNetworks, Inc., a leading digital media services and ....

Regeneron Pharmaceuticals Inc. and Alnylam Pharmaceuticals Inc. have reportedly entered into a definitive collaborative deal. Authentic sources claim that the deal has been inked in a major effort to discover, advance and commercialize trea....

The strategic partnership is aimed at jointly developing a new immuno-stimulatory therapy for certain neurologic disorders. I-Mab Biopharma, a Shanghai-based biotech company, along with the CNS (Central Nervous System) drug development com....

An online petition had called on Google to single out Kay Coles James (Heritage Foundation) from the council that was formed a week ago. Technology giant Google has confirmed the dissolution of its recently formed AI ethics advisory panel ....

·         Liquid will use the capital for offering new services and expanding into new markets ·         The firm has said that it is publicly in....

The companies will develop business solutions that include solar panels, batteries, recycling of new generation car batteries and electric transport Reports confirms that Vattenfall and Boliden have entered into an agreement to jointly ass....

A joint venture will combine IPS Specials’ abilities as a licensed pharma importer with medical cannabis expertise of Grow Biotech Reports confirm that IPS Specials and Grow Biotech will ink a joint venture agreement for creating a n....

New data describes that a combination of Innate’s anti-CD39 monoclonal antibody and ATP-inducing oxaliplatin had enhanced the control of tumor growth Innate Pharma has reportedly announced that new preclinical data from the innovativ....